
|Articles|November 20, 2020
Full Characterization in Early Method Development
Author(s)SGS
This whitepaper will look at how integrating the SEC-MALS method at an earlier stage in the development process will accelerate speed-to-clinic without compromising patient safety.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Trending on BioPharm International
1
Year in Review: How FDA Guidances Defined the 2025 Biopharma Landscape
2
AI, CRISPR, and mRNA Driving Biotech’s Smartest Decade Yet
3
Top BP Videos of 2025: An Intersection of AI, Innovation, and Compliance
4
Conjugation and Regulation Challenges for Advanced Molecules: Part Two of Three with Abzena
5